Compare with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES WOCKHARDT ALKEM LABORATORIES/
WOCKHARDT
 
P/E (TTM) x - -19.5 - View Chart
P/BV x 6.7 1.0 651.1% View Chart
Dividend Yield % 0.6 0.0 17,258.2%  

Financials

 ALKEM LABORATORIES   WOCKHARDT
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
WOCKHARDT
Mar-18
ALKEM LABORATORIES/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,5891,012 157.0%   
Low Rs1,232532 231.8%   
Sales per share (Unadj.) Rs417.5355.9 117.3%  
Earnings per share (Unadj.) Rs56.3-60.3 -93.4%  
Cash flow per share (Unadj.) Rs64.7-46.8 -138.4%  
Dividends per share (Unadj.) Rs12.700.01 127,000.0%  
Dividend yield (eoy) %0.90 69,487.6%  
Book value per share (Unadj.) Rs292.9257.8 113.6%  
Shares outstanding (eoy) m119.57110.63 108.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.2 155.8%   
Avg P/E ratio x25.1-12.8 -195.7%  
P/CF ratio (eoy) x21.8-16.5 -132.1%  
Price / Book Value ratio x4.83.0 160.9%  
Dividend payout %22.60 -135,984.3%   
Avg Mkt Cap Rs m168,65385,379 197.5%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m9,1719,371 97.9%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m49,91539,369 126.8%  
Other income Rs m1,6451,202 136.8%   
Total revenues Rs m51,56140,571 127.1%   
Gross profit Rs m8,48218 46,351.4%  
Depreciation Rs m1,0061,495 67.3%   
Interest Rs m6712,555 26.2%   
Profit before tax Rs m8,451-2,830 -298.7%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,606257 624.9%   
Profit after tax Rs m6,731-6,669 -100.9%  
Gross profit margin %17.00 36,558.0%  
Effective tax rate %19.0-9.1 -209.2%   
Net profit margin %13.5-16.9 -79.6%  
BALANCE SHEET DATA
Current assets Rs m27,06233,796 80.1%   
Current liabilities Rs m15,32426,917 56.9%   
Net working cap to sales %23.517.5 134.6%  
Current ratio x1.81.3 140.7%  
Inventory Days Days6779 83.8%  
Debtors Days Days4189 46.3%  
Net fixed assets Rs m12,61039,664 31.8%   
Share capital Rs m239553 43.2%   
"Free" reserves Rs m34,49027,968 123.3%   
Net worth Rs m35,02728,522 122.8%   
Long term debt Rs m1,21221,731 5.6%   
Total assets Rs m54,38781,620 66.6%  
Interest coverage x13.6-0.1 -12,650.9%   
Debt to equity ratio x00.8 4.5%  
Sales to assets ratio x0.90.5 190.3%   
Return on assets %13.6-5.0 -270.0%  
Return on equity %19.2-23.4 -82.2%  
Return on capital %24.9-7.7 -323.9%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,5639,807 66.9%   
Fx outflow Rs m3,0121,789 168.4%   
Net fx Rs m3,5528,019 44.3%   
CASH FLOW
From Operations Rs m7,259684 1,060.6%  
From Investments Rs m1,8646,302 29.6%  
From Financial Activity Rs m-9,273-7,695 120.5%  
Net Cashflow Rs m-150-664 22.6%  

Share Holding

Indian Promoters % 66.9 74.5 89.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 2.3 1,439.1%  
FIIs % 0.0 7.7 -  
ADR/GDR % 0.0 0.1 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 67,757 100.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Oct 18, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - SHASUN PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS